Hims & Hers Health has experienced a significant surge in international revenue, growing over 17-fold year-over-year to $131 million, driven by its acquisition of Eucalyptus and expansion into new markets. The company aims to exceed $600 million in international revenue by 2026. Investments in AI are expected to reduce customer support costs and improve retention, with payback anticipated within 12 to 18 months. Additionally, its testosterone therapy is rapidly scaling and is set to become the company's sixth U.S. specialty treatment generating over $100 million, with further growth potential through new offerings and cross-selling.
Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting...
Berger Montague PC has initiated an investigation into Hims & Hers Health, Inc.'s Board of Directors over potential breaches of fiduciary duties. The probe focuses on allegations that the company improperly shared private user health data with advert...
Hims & Hers Health, Inc. is under investigation after the FTC sued the company for allegedly sharing customers' medical information with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful p...
